Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06138756 · ClinicalTrials.gov registry record
Acute Treatment of Migraine in Pre-Adolescents: Real-World Analysis of Remote Electrical Neuromodulation (REN)
A clinical trial, sponsored by Theranica.
- Completed
- Registry status
- 293
- Enrollment target
NCT06138756 is a clinical trial that has completed, run by Theranica. The registered enrollment target is 293 participants.
The verdict
NCT06138756 has completed, sponsored by Theranica.
- COMPLETED
- Registry status
- 293 participants
- Enrollment target
Study Summary
Migraine is a prevalent neurological disorder that severely impacts both children and adolescents, causing significant disability. Remote Electrical Neuromodulation (REN) is a nonpharmacological, prescribed, wearable device, FDA-cleared for acute and/or preventive treatment of migraine with or without aura in patients 12 years or older. Multiple studies have shown that REN has high safety, tolerability, and efficacy in adults and adolescents. This study aims to evaluate REN's real-world safety and efficacy in pre-adolescents, 6-11 years old.
Interventions
- DEVICE Nerivio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 293 participants |
| Start Date | 2023-10-01 |
| Est. Completion | 2024-06-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06138756
The ClinicalTrials.gov registry entry for NCT06138756 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 293 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theranica, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nerivio is the first listed.
NCT06138756 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06138756 about?
NCT06138756 is a clinical study titled "Acute Treatment of Migraine in Pre-Adolescents: Real-World Analysis of Remote Electrical Neuromodulation (REN)". Migraine is a prevalent neurological disorder that severely impacts both children and adolescents, causing significant disability. Remote Electrical Neuromodulation (REN) is a nonpharmacological, prescribed, wearable device, FDA-cleared for acute and/or preventive treatment of migraine with or witho...
What is the current status of trial NCT06138756?
This trial is currently completed. The enrollment target is 293 participants. The study started on 2023-10-01. Estimated completion is 2024-06-01.
What interventions are being tested in trial NCT06138756?
The interventions under investigation include: Nerivio (DEVICE).
Who is sponsoring clinical trial NCT06138756?
This trial is sponsored by Theranica, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.